Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;65(3):266-272.
doi: 10.5468/ogs.21261. Epub 2022 Mar 28.

Effect of autologous platelet-rich plasma for treatment of recurrent pregnancy loss: a randomized controlled trial

Leila Nazari  1   2   3 , Saghar Salehpour  1   2   3 , Sedighe Hosseini  1   2   3 , Teibeh Hashemi  1   2   3 , Nasrin Borumandnia  4 , Elham Azizi  1
Affiliations

Effect of autologous platelet-rich plasma for treatment of recurrent pregnancy loss: a randomized controlled trial

Leila Nazari et al. Obstet Gynecol Sci. 2022 May.

Abstract

Objective: Recurrent pregnancy loss (RPL) is a fertility problem for which no exact mechanism of abortion or efficient treatment has been described. This study was conducted between 2018 and 2019 to investigate the effectiveness of autologous platelet-rich plasma (PRP) in improving the live birth rate of women with RPL who required in vitro fertilization (IVF).

Methods: A total of 63 patients with at least two previous pregnancy losses and no specific cause detected for the RPL were included and randomly assigned into two groups (PRP and control). Intrauterine infusion of 0.5 mL of autologous PRP was performed 48 hours before embryo transfer in the PRP group. Women in the control group received standard treatment.

Results: Forty patients completed the study. The baseline and cycle characteristics of the participants did not differ significantly between the PRP and control groups. The clinical pregnancy rate was higher in the PRP group (35% vs. 20%, P=0.288). The live birth rate was 15% in the PRP group, but no live births were recorded in the control group (P=0.231).

Conclusion: This is the first study to show that intrauterine infusion of PRP in patients with RPL who undergo IVF may increase the chance of live birth.

Keywords: In vitro fertilization; Live-birth; Platelet-rich plasma; Recurrent pregnancy loss.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
The consolidated standards of reporting trials flowchart. PRP, platelet-rich plasma.
See this image and copyright information in PMC

References

    1. Egerup P, Kolte AM, Larsen EC, Krog M, Nielsen HS, Christiansen OB. Recurrent pregnancy loss: what is the impact of consecutive versus non-consecutive losses? Hum Reprod. 2016;31:2428–34. - PubMed
    1. The ESHRE Guideline Group on RPL. Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S, et al. ESHRE guideline: recurrent pregnancy loss. 1st ed. Oxford: Oxford University Press; 2018. - PMC - PubMed
    1. Ticconi C, Pietropolli A, Di Simone N, Piccione E, Fazleabas A. Endometrial immune dysfunction in recurrent pregnancy loss. Int J Mol Sci. 2019;20:5332. - PMC - PubMed
    1. Di Nicuolo F, D’Ippolito S, Castellani R, Rossi ED, Masciullo V, Specchia M, et al. Effect of alpha-lipoic acid and myoinositol on endometrial inflammasome from recurrent pregnancy loss women. Am J Reprod Immunol. 2019;82:e13153. - PubMed
    1. Baradwan S, Abdulghani SH, Abuzaid M, Khadawardi K, Alshahrani MS, Al-Matary A, et al. 17-alpha hydroxy-progesterone caproate for the prevention of recurrent preterm birth among singleton pregnant women with a prior history of preterm birth: a systematic review and meta-analysis of six randomized controlled trials. Obstet Gynecol Sci. 2021;64:484–95. - PMC - PubMed